一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (242k)
Article in Japanese

Case Report

Safety and efficacy of pemetrexed monotherapy for previously treated patients with non-small cell lung cancer and interstitial pneumonia

Kazumasa Ogawaa  Hironori Urugaa,b  Yui Takahashia  Makiko Takeyasua  Toshitaka Satoa  Sayaka Mochizukia  Shigeo Hanadaa  Shinko Suzukia  Atsuko Kurosakic  Kazuma Kishia,b 

aDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital
bOkinaka Memorial Institute for Medical Research
cDepartment of Clinical Radiology, Fukujuji Hospital

ABSTRACT

Lung cancer often develops in patients with interstitial pneumonia (IP). Chemotherapy for lung cancer patients who have IP is difficult because of the increased likelihood of acute exacerbations (AE) of IP or chemotherapy-induced pneumonitis. Furthermore, little is known regarding chemotherapy for previously treated patients having lung cancer associated with IP. We retrospectively evaluated the safety and efficacy of pemetrexed monotherapy for previously treated patients with non-small cell lung cancer (NSCLC) and IP. We enrolled 50 NSCLC patients and evaluated 5 patients with IP from among them. The median age was 68 years. The treatment line of pemetrexed included second line in two patients, and third line or more in three. The response rate was 0%, and the disease control rate (complete response+partial response+stable disease) was 60%. Pemetrexed-induced pneumonitis occurred in two patients (40%). The two patients who developed pneumonitis had mild IP. Therefore special attention should be paid when using pemetrexed for previously treated patients with lung cancer and IP, even for mild stage IP.

KEYWORDS

Interstitial pneumonia  Pemetrexed  Non-small cell lung cancer  Acute exacerbation  Drug-induced pneumonitis 

Received 6 Aug 2013 / Accepted 14 Jan 2014

AJRS, 3(3): 405-409, 2014

Google Scholar